Uncategorized

Babson Diagnostics today announced the addition of a clinical advisor who will bring valuable insights of the medical community in the ongoing development and introduction of the company’s new diagnostic blood testing service, BetterWay™. Andrew Carroll, M.D., a family physician and clinical assistant professor at the University of Arizona College of Medicine, will provide advice […]

Horizon Therapeutics plc Announces Positive Topline Data from TEPEZZA ® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED).

AbbVie and Johnson & Johnson will withdraw the accelerated approvals for Imbruvica in mantle cell lymphoma and marginal zone lymphoma, the companies announced Thursday.

JW Therapeutics announced that it has received the Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) of China for a clinical trial of relmacabtagene autoleucel injection (relma-cel) in patients with moderately or severely refractory systemic lupus erythematosus (SLE).

Regenative Labs announced that it will present two scientific studies demonstrating the efficacy of Wharton’s jelly allografts in complicated post-surgical wounds and late-stage sacral decubitus ulcers at the Symposium on Advanced Wound Care (SAWC) conference.

Astrocyte Pharmaceuticals Announces Theodore Liston, Ph.D., Vice President of Research, as Recipient of the 2022 Innovation and Progress Award from the Journal Stroke.

Currently, there are no gene editing–based treatments on the market, but the technology continues its march toward potential FDA approval, with several products in mid- and late-stage trials.

Evecxia Therapeutics, Inc. today announced favorable safety, tolerability, pharmacokinetic, and pharmacodynamic data from a double-blind, placebo-controlled Phase 1, a two-part single ascending dose (SAD) and multiple ascending dose (MAD) trial of EVX-101 in healthy volunteers treated with escitalopram.

Aviceda is partnering with world-renowned scientist Professor Christopher Scott and his teams at the Patrick G. Johnson Centre for Cancer Research at Queen’s University Belfast to spearhead development of the next generation of glyco-immune therapeutics.

Virginia Commonwealth University’s Stravitz-Sanyal Institute for Liver Disease and Metabolic Health has announced a partnership with Singapore -headquartered medtech company, Histoindex Pte Ltd.